Federated Hermes, Inc. Aeglea Bio Therapeutics, Inc. Transaction History

Federated Hermes, Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$0.5 - $2.66 $965 - $5,133	1,930 New	1,930 $1,000
Q4 2020 Feb 12, 2021	SELL	$7.02 - $9.83 $2,646 - $3,705	-377 Closed	0 $0
Q3 2020 Nov 12, 2020	BUY	$6.51 - $9.33 $91 - $130	14 Added 3.86%	377 $3,000
Q2 2020 Aug 13, 2020	BUY	$4.01 - $11.04 $1,455 - $4,007	363 New	363 $3,000
Q1 2019 May 10, 2019	SELL	$7.6 - $9.4 $3,876 - $4,794	-510 Closed	0 $0
Q4 2018 Feb 13, 2019	SELL	$6.51 - $10.19 $5,168 - $8,090	-794 Reduced 60.89%	510 $3,000
Q3 2018 Nov 13, 2018	SELL	$8.24 - $11.0 $1,804 - $2,409	-219 Reduced 14.38%	1,304 $12,000
Q2 2018 Aug 10, 2018	BUY	$7.87 - $10.89 $5,871 - $8,123	746 Added 96.01%	1,523 $16,000
Q1 2018 May 09, 2018	BUY	$5.07 - $10.9 $3,939 - $8,469	777 New	777 $8,000

241K

Ticker AGLE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,172,500
Market Cap $1.69B
Description
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy f...

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

Stay updated on Federated Hermes, Inc. with notifications on news.